CAC 40
8 234,33 +46,68 (+0,57 %) Euro Stoxx 50
5 083,49 +29,08 (+0,58 %) Dow Jones
39 387,76 +331,36 (+0,85 %) EUR/USD
1,0786 +0,0002 (+0,02 %) Gold future
2 375,00 +34,70 (+1,48 %) Bitcoin EUR
58 415,37 +1 540,41 (+2,71 %)
Supernus Pharmaceuticals, Inc. (SUPN)
Échanges après Bourse :
Supernus Pharmaceuticals, Inc.
9715 Key West Avenue
Rockville, MD 20850
United States
301 838 2500
https://www.supernus.com
Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - Specialty & Generic
Employés à temps plein: 652
Dirigeants clés
| Nom | Titre | Payer | Exercé | Année de naissance |
|---|---|---|---|---|
| Mr. Jack A. Khattar | Founder, President, CEO, Secretary & Director | 1,84M | 2,34M | 1961 |
| Mr. Timothy C. Dec | Senior VP & CFO | 704,03k | S.O. | 1959 |
| Dr. Padmanabh P. Bhatt Ph.D. | Chief Scientific Officer & Senior VP of Intellectual Property | 628,41k | 153,93k | 1957 |
| Mr. Frank Mottola | Senior Vice President of Quality, GMP Operations, Information Technology and Regulatory Affairs | 526,48k | 37,78k | 1973 |
| Dr. Jonathan Rubin M.D., MBA | Senior VP of Research & Development and Chief Medical Officer | 662,53k | S.O. | 1961 |
| Mr. Kevin T. Anderson Esq. | Compliance Officer | S.O. | S.O. | 1962 |
| Dr. Todd Horich M.B.A., Ph.D. | Senior Vice President of Marketing & Market Access | S.O. | S.O. | S.O. |
| Mr. Taylor Raiford | Senior Vice President of Sales | S.O. | S.O. | S.O. |
| Dr. Bryan A. Roecklein Ph.D. | Senior Vice President of Corporate Development | S.O. | S.O. | S.O. |
| Mr. Jeff Bozick | Senior Vice President of Supply Chain | S.O. | S.O. | S.O. |
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.
Gouvernance d’entreprise
L’ISS Governance QualityScore de Supernus Pharmaceuticals, Inc. en date du 1 mai 2024 est 6. Les scores principaux sont Audit : 9; Société : 4; Droits des actionnaires : 7; Compensation : 5.
